<p>A total of six spots changed significantly in relation to Darbepoietin-α treatment alone, two graphs for each of the spots A-F are shown. Left panel show the average change in spot intensity for the sedentary-ESA group (n = 9). The dark grey box at the bottom indicates the boosting period (first 3 weeks) and the light grey box the maintenance period (weeks 4–10), subjects were not treated during weeks 11–13 (wash-out phase). Data are expressed as mean ± SE, level of significance are p<0.05, * indicates difference from baseline (week 0) and # difference from the week number given below. Right panel shows individual changes (%) from baseline in all subjects. Black bars; week 3, light grey; week 10, dark grey; week 13.</p
(A) according to lipid-lowering and antiplatelet drugs; (B) for combined therapies. Simvastatin/ezet...
<p>Levels of Aβ42 in peripheral-plasma and jugular-plasma in each participant are represented by whi...
<p>Data for the <i>a </i><i>priori</i> defined regions of interest in NL (top row), MCI (middle row)...
<p>Average spot intensity for spots B, D, and H, which showed an overall training effect. SP (sedent...
<p>Subject 5 had an additional treatment break from weeks 101 to 128 inclusive. Subjects 1, 2, 5, 6,...
Changes in tissue area mean blur rate as percentages (%MT) during the evaluation of the effects of t...
<p>Left row shows scatter plots of scores of plaque stage and plaque cholesterol content of the seve...
<p>Note: The differential protein spots had >2.0-fold changes in the DKA treatment groups compared t...
<p>Average number of possibly and probably related (both solicited and unsolicited) AE per previousl...
<p>Box plots for each disease activity measures at baseline, 1 year and 2 years after are displayed ...
<p>The individual total serum haptoglobin levels in the sedentary-ESA and training-ESA groups, respe...
<p>Abbreviations: MTA-ERC, medial temporal areas including the entorhinal cortex; WBC, whole brain c...
<p>Skin luminance was determined before (week 0), during (week 5), and at the end (week 7) of the in...
<p>The first row of panels shows the results of simulations for the low-risk sub-population where th...
Changes in vessel area mean blur rate as percentages (%MV) during the evaluation of the effects of t...
(A) according to lipid-lowering and antiplatelet drugs; (B) for combined therapies. Simvastatin/ezet...
<p>Levels of Aβ42 in peripheral-plasma and jugular-plasma in each participant are represented by whi...
<p>Data for the <i>a </i><i>priori</i> defined regions of interest in NL (top row), MCI (middle row)...
<p>Average spot intensity for spots B, D, and H, which showed an overall training effect. SP (sedent...
<p>Subject 5 had an additional treatment break from weeks 101 to 128 inclusive. Subjects 1, 2, 5, 6,...
Changes in tissue area mean blur rate as percentages (%MT) during the evaluation of the effects of t...
<p>Left row shows scatter plots of scores of plaque stage and plaque cholesterol content of the seve...
<p>Note: The differential protein spots had >2.0-fold changes in the DKA treatment groups compared t...
<p>Average number of possibly and probably related (both solicited and unsolicited) AE per previousl...
<p>Box plots for each disease activity measures at baseline, 1 year and 2 years after are displayed ...
<p>The individual total serum haptoglobin levels in the sedentary-ESA and training-ESA groups, respe...
<p>Abbreviations: MTA-ERC, medial temporal areas including the entorhinal cortex; WBC, whole brain c...
<p>Skin luminance was determined before (week 0), during (week 5), and at the end (week 7) of the in...
<p>The first row of panels shows the results of simulations for the low-risk sub-population where th...
Changes in vessel area mean blur rate as percentages (%MV) during the evaluation of the effects of t...
(A) according to lipid-lowering and antiplatelet drugs; (B) for combined therapies. Simvastatin/ezet...
<p>Levels of Aβ42 in peripheral-plasma and jugular-plasma in each participant are represented by whi...
<p>Data for the <i>a </i><i>priori</i> defined regions of interest in NL (top row), MCI (middle row)...